Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.51 |
| ▸ | CHUK | O15111 | 4/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.49 |
| ▸ | CDC42BPB | Q9Y5S2 | 5/20 | 0.49 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522171 | 0.81 | LRRK2 (0.40) | MAP3K7TAB1LRRK2CHUKHSP90AB1 | |
| SCHEMBL154683 | 0.80 | CHUK (0.61) | MAP3K7TAB1LRRK2CHUKHSP90AB1 | |
| SCHEMBL14649086 | 0.80 | MAP3K7 (0.56) | MAP3K7TAB1LRRK2CHUKHSP90AB1 | |
| SCHEMBL12590787 | 0.78 | CHUK (0.48) | MAP3K7TAB1LRRK2CHUKHSP90AB1 | |
| SCHEMBL19185239 | 0.77 | MAP3K7 (0.54) | MAP3K7TAB1LRRK2CHUKHSP90AB1 | |
| SCHEMBL6311834 | 0.76 | CHUK (0.71) | CHUK | |
| SCHEMBL18844347 | 0.76 | MAP3K7 (0.38) | MAP3K7TAB1LRRK2CHUKHSP90AB1 | |
| SCHEMBL5527750 | 0.76 | RET (0.38) | MAP3K7TAB1LRRK2CHUKHSP90AB1 | |
| SCHEMBL14670863 | 0.76 | MAP3K7 (0.52) | MAP3K7TAB1LRRK2CHUKHSP90AB1 | |
| SCHEMBL17401156 | 0.76 | MAP3K7 (0.56) | MAP3K7TAB1LRRK2CHUKHSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-6342501-B1 | VIRICIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-01-29 | — | — | US | disclosed |
| WO-2000042043-A1 | PYRROLO[2,3-d]PYRIMIDINES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5543413-A | VIRAL ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS AND HERPES SIMPLEX VIRUS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1996-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | MAP3K7 2479/4885TAB1 2996/4885LRRK2 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.